Rocklatan (Netarsudil and Latanoprost Ophthalmic Solution) for Glaucoma: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players – Alcon and Aerie Pharmaceuticals

Rocklatan (Netarsudil and Latanoprost Ophthalmic Solution) for Glaucoma: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players - Alcon and Aerie Pharmaceuticals
DelveInsight has recently published a report on “Rocklatan Market Forecast Report” providing an in-depth analysis of the Rocklatan market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The comprehensive report provides an analysis of Rocklatan market potential and market share analysis in the Glaucoma therapeutics space across the 7MM from 2019 to 2032. The report also helps you to understand the Rocklatan clinical and commercial developments along with parameters like the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.

Rocklatan Drug Insight

ROCKLATAN (netarsudil and latanoprost ophthalmic solution) presents a groundbreaking advancement in ocular health, being a 0.02%/0.005 fixed-dose combination featuring a Rho kinase inhibitor and a prostaglandin F2α analog. This unique formulation is specifically indicated for the reduction of elevated intraocular pressure (IOP) in individuals dealing with open-angle glaucoma or ocular hypertension. In the European market, this innovative medication is marketed under the trade name ROCLANDA.

What sets ROCKLATAN apart is its dual-action mechanism, combining the efficacy of a Rho kinase inhibitor with the benefits of a prostaglandin analog. This comprehensive approach not only addresses elevated IOP but also makes ROCKLATAN the first and only fixed-dose combination product in the United States that includes a prostaglandin for intraocular pressure reduction. Moreover, it stands out as the sole fixed-dose combination product available in the United States that requires once-daily dosing, simplifying the treatment regimen for patients.

The convenience and efficacy of ROCKLATAN contribute to its significance in the field of ophthalmology, providing healthcare professionals with a powerful tool in the management of glaucoma and ocular hypertension. This novel combination product represents a promising option for individuals seeking a streamlined approach to their eye health. As it continues to make strides in the realm of ocular therapeutics, ROCKLATAN remains a beacon of progress and innovation. 

Rocklatan Clinical Development

The FDA approval of Rocklatan is based on data from two phase 3 registration trials, MERCURY 1 and MERCURY 2. In these studies, Rocklatan achieved its primary 90-day efficacy endpoint as well as positive 12-month safety and efficacy results, demonstrating statistically superior IOP reduction over latanoprost and netarsudil at every measured time point. More than 60% of patients taking Rocklatan in the two MERCURY studies achieved an IOP reduction of 30% or more, a frequency that was nearly twice that achieved by participants taking latanoprost alone. Rocklatan also helped more patients get to low target pressures. Nearly twice as many patients taking Rocklatan reached 16 mmHg or lower and nearly three times as many reached 14 mmHg or lower compared to latanoprost.

Commercial Development Activity

Aerie launched Rhopressa in the United States in April 2018. However, in November 2022, Alcon announced the successful completion of its acquisition of Aerie Pharmaceuticals Inc. This strategic move is poised to strengthen Alcon’s position in the ophthalmic pharmaceutical sector, augmenting its portfolio of commercial products and development pipeline.

As part of the deal, Alcon has incorporated key commercial products such as netarsudil and latanoprost ophthalmic solution 0.02%/0.005% (Rocklatan) and netarsudil ophthalmic solution 0.02% (Rhopressa). Additionally, the acquisition includes AR-15512, a Phase 3 product candidate targeting dry eye disease. Alcon has also gained access to a promising pipeline of ophthalmic pharmaceutical product candidates, providing an opportunity to capitalize on Aerie’s established research and development capabilities.

Stay ahead of the competition by leveraging key insights and evolving trends in the Rocklatan Market @

Key Highlights of the Rocklatan Market Report

  • The report contains forecasted sales evaluation of Rocklatan for Glaucoma till 2032.
  • It provides comprehensive coverage of late-stage emerging therapies for Glaucoma treatment.
  • The report also features qualitative and quantitative analysis with analysts, as well as KOL views for Rocklatan in Glaucoma.

Why Rocklatan Market Report?

  • The projected market data for Rocklatan in the context of glaucoma will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of Rocklatan, aiding in strategic planning and decision-making processes within the therapeutic domain.
  • A comprehensive market forecast for Rocklatan will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug’s positioning, potential market share, and its overall impact on the competitive environment in the therapeutic field.
  • Conducting a thorough market forecast for Rocklatan will facilitate a detailed analysis of the drug’s clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of Rocklatan. 
  • The report additionally offers future market assessments for the Rocklatan market in the field of Glaucoma across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of Glaucoma. This multifaceted approach ensures a comprehensive understanding of the Rocklatan market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.

Download the sample report to learn more about the evolving market dynamics @



Related Reports By DelveInsight:

Glaucoma Pipeline Insight

DelveInsight’s, “Glaucoma Pipeline Insight” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Some of the key companies in the Glaucoma TTakeda, Argenx, Keros Therapeutics, Principia Biopharma, Momenta Pharmaceuticals, Veralox Therapeutics, Novartis Pharmaceuticals, Pfizer, HUTCHMED, Genosco, UCB, and others.  

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Unlock success with our Product Assessment case study. Gain valuable insights for strategic decision-making and product optimization in your industry @

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States